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INTRODUCTION
Ambulatory  anaesthesia  is  one  administered  for  elective  surgical  procedure 
performed on carefully selected patients,  which is undertaken with all  its constituent 
elements (admission, surgery and discharge home) on the same day.  It is also referred to 
as  day  case,  day  care  or  outpatient  anaesthesia  and  more  recently  office  -  based 
anaesthesia.
Ambulatory anaesthesia is a rapidly growing subspecialty.  Although its history is 
as old as the history of general anaesthesia itself, it has emerged as a recognized concept 
and is evolving over the past couple of decades.
In the US, it comprises 70 percent of anaesthesia services provided.  In the UK, the 
NHS plan, published recently predicts that 75 percent of elective surgical procedures 
will soon be conducted as day cases.  Back home, 70 percent of elective surgeries that 
qualify the criteria are performed as day cases in Hinduja Hospital, Mumbai.
Anaesthetic agents today have been designed and marketed to meet specific niche 
criteria for ambulatory anaesthesia. Among the agents available in India, propofol and 
sevoflurane have increased the ability of the anaesthesiologist to provide a successful 
day case experience.
The present study compares the induction and recovery characteristics of these two 
anaesthetic drugs and their usefulness in ambulatory anaesthesia.
AIM OF THE STUDY
The aim of the study is to compare the induction and recovery characteristics of 
propofol  and sevoflurane by the time to loss of consciousness,  incidence of  apnoea, 
induction  complications,  recovery  times  and  incidence  of  postoperative  nausea, 
vomiting & pain when they are  used as  sole  induction and maintenance  anaesthetic 
agent in adult tonsillectomies.
                              AMBULATORY ANAESTHESIA
In the early 1900s,  an American anaesthesiologist,  Ralph Waters conceptualized 
ambulatory anaesthesia.  There was little interest in ambulatory surgical care until the 
late  1960s,  when the  first  hospital  based ambulatory  surgical  units  were  developed. 
Over  the  last  two  decades,  outpatient  surgery  has  grown  at  an  exponential  rate, 
progressing from the practice of performing simple procedures on healthy outpatients to 
encompassing  a  broad  spectrum of  patient  care  in  freestanding  ambulatory  surgery 
centers.
The surgery may be done in a hospital, a freestanding surgery centre or in some 
cases, a surgeon’s office.  Anaesthesia care is given or supervised by anaesthesiologist.
The  advantages  of  lower  cost,  lower  rate  of  hospital  acquired  infection,  less 
separation of patients from their home and family environment, less patient anxiety and 
greater patient convenience have  been demonstrated by this sub-specialty over a period 
of five decades.  It was well established that paediatric patients recovered better at home 
without separating from their mothers. 
Patients save money by less preoperative laboratory tests and fewer post operative 
medications and by recovering at  home.   They are continued to  be employed while 
recuperating, thus beds are free for the hospital for sicker patients and for emergency 
surgeries.  Patients have the greater flexibility in selecting the time of their operation.
Newer anaesthetic drugs allow patients to recover faster, permitting the number and 
the complexity of cases to include longer and more complex procedures, permitting a 
safer operation theatre without flammable anaesthetics.  (Appropriate pain management 
and prophylaxis for PONV is included as part of the discharge planning.)
Technology has offered sophisticated monitors to monitor patients more carefully 
during  anaesthesia,  thus  permitting  sicker  patients  with  more  challenging  medical 
conditions to be considered for ambulatory anaesthesia.
There are several types of anaesthetic techniques available for ambulatory surgery 
ranging  from  local  anaesthesia  to  general  anaesthesia.   The  anaesthetic  technique 
recommended depends on several factors like the surgical procedure, the medical history 
of the patient and the patient’s preference.
The four anaesthetic options are:
• General anaesthesia
• Regional anaesthesia
• Monitored anaesthesia care
• Local anaesthesia
     General anaesthesia with regional anaesthesia for post operative pain relief is an ideal 
combination as it combines the advantages of both the comfort and lack of awareness in 
the former and the good quality of pain relief with the later.
PHARMACOLOGY OF PROPOFOL
     Propofol  is  a  substituted  isopropyl  phenol  (2,  6  -  di  isopropyl  phenol)  that  is 
administered intravenously as 1 % solution in an aqueous solution of 10 % soybean oil,  
2.25% glycerol and 1.2% purified egg phosphatide.  This drug is chemically distinct 
from all other drugs that act as intravenous sedative - hypnotics.
     Administration of propofol, 1.5 to 2.5 mg/kg as a rapid IV injection (<15 secs), produces 
unconsciousness within about 30 seconds.  Awakening is more rapid and complete than that after 
induction of anaesthesia with all other drugs.     
     The more rapid return of consciousness with minimal residual central nervous system 
effects is one of the most important advantages of propofol.
MECHANISM OF ACTION
     Propofol  is  presumed  to  exert  it’s  sedative  -  hypnotic  effects  through  an 
interaction with GABA receptor, the principal inhibitory neurotransmitter in the central 
nervous  system.   When  GABA  receptor  is  activated,  transmembrane  chloride 
conductance increases, resulting in hyperpolarisation of the post synaptic cell membrane 
and functional inhibition of the postsynaptic neuron.  The interaction of propofol with 
specific components of GABAA receptors appears to decrease the rate of dissociation of 
the inhibitory neurotransmitter, GABA from the receptor, thereby increasing the duration 
of  the  GABA   activated  opening  of  the  chloride  channel  with  resulting  hyper 
polarization of cell membranes.
PHARMACOKINETICS
     Hepatic metabolism and tissue uptake (possibly into the lungs) are both important 
in removal of this drug from the plasma.  Hepatic metabolism is rapid and extensive, 
resulting in inactive, water - soluble sulphate and glucuronic acid conjugates that are 
excreted  by  the  kidneys.   The  elimination  half  time  is  0.5  to  1.5  hours,  but  more 
important, the context - sensitive half time for propofol infusions lasting up to 8 hours is 
< 40 minutes.  The context - sensitive half  time of propofol is minimally influenced by 
the  duration  of  infusion  because  of  rapid  metabolic  clearance  when  the  infusion  is 
discontinued, such that drug that returns from tissue storage sites to the circulation is not 
available to retard the decrease in plasma concentrations of the drug.
Propofol, (like thiopentone and alfentanil) has a short effect - site equilibration 
time.
There is no evidence of impaired elimination in patients with cirrhosis of the liver. 
Renal  dysfunction  also  does  not  influence  the  clearance  of  propofol  despite  the 
observation that nearly three - fourths of propofol metabolites are eliminated in urine in 
the first 24 hours.
Propofol  readily crosses the placenta,  but  is  rapidly cleared from the neonatal 
circulation.
     Volume of distribution  -   3.5 - 4.5 L/kg
     Clearance                      -   30 ml /kg/ min
Pharmacodynamics
Cardiovascular system
Propofol produces decreases in systemic blood pressure that are greater than those 
evoked by comparable doses of thiopentone.  This decrease is often accompanied by 
decrease in cardiac output due to negative inotropic  effect  and decrease in systemic 
vascular resistance due to inhibition of sympathetic vasoconstrictor nerve activity.  The 
hypotensive effects are generally proportional to the dose and the rate of administration 
of propofol, and may be potentiated by opioid analgesics.
Propofol blunts the pressor response to direct laryngoscopy and intubation more 
effectively  than thiopentone.   It  also  effectively  blunts  the  hypertensive  response  to 
placement of a LMA.
Despite decreases in systemic blood pressure, heart rate often remains unchanged 
in contrast to the modest increases that typically accompany the rapid IV injection of 
thiopental.  Bradycardia and asystole have been observed after induction.  The incidence 
being 1.4 in 100,000.
Unlike sevoflurane, propofol does not prolong the QTc  interval on the ECG.  It 
does not alter SA or AV nodal function in normal patients or in patients with Wolff -  
Parkinson- White syndrome.
Lungs
     Propofol produces dose - dependent depression of ventilation, with apnoea occurring 
in 25% to 35% of patients after induction of anaesthesia with propofol.  Opioids given as 
premedication enhance this
ventilatory  depressant  effect.   A maintenance  infusion  of  propofol  decreases  tidal 
volume and respiratory rate.
The ventilatory response to carbon dioxide and arterial hypoxemia are decreased 
by propofol.  The decreased ventilatory response to hypercapnia is due to the effect at 
the central chemoreceptors.  In contrast to low- dose volatile anaesthetics, the peripheral 
chemoreflex response to carbon dioxide remains intact.  
Propofol can produce bronchodilatation and decrease the incidence of intraoperative wheezing in 
patients with asthma. And propofol does not cause laryngospasm.
Central Nervous System
Propofol decreases cerebral blood flow, cerebral metabolic oxygen consumption 
and  intracranial  pressure.   It  also  increases  cerebrovascular  resistance  but  does  not 
appear to affect cerebrovascular reactivity to changes in arterial carbon dioxide tension.
Other systems
Propofol  anaesthesia  is  associated  with  significant  decreases  in  intraocular 
pressure by as much as 30 to 50 %.  This decrease may be associated with a concomitant 
decrease in systemic vascular resistance.
     Although propofol has the potential for affecting adrenal steroidogenesis, it does 
not appear to block cortisol and aldosterone secretion in response to surgical stress or 
adrenocorticotropic hormone (ACTH) in clinical practice.  Although transient decreases 
in  plasma  cortisol  concentrations  have  occurred,  these  reductions  have  not  been 
sustained.
Side Effects
Allergic Reactions
     Allergic components of propofol include the phenyl nucleus and di isopropyl side 
chain.  Allergic reactions are described in patients with history of other drug allergies, 
often to neuromuscular blocking drugs.
Lactic acidosis
     Or “Propofol infusion syndrome” is described in patients receiving prolonged high-
dose  infusions  of  propofol  (>75µg/kg/mnt)  for  longer  than  24  hours.   Unexplained 
tachycardia occurring during propofol anaesthesia should prompt evaluation.
Other side effects include
1. Abuse potential
2. Bacterial growth – the contents of an opened vial must be discarded if they are not 
used within six hours.
3. Pain  on  injection  –  1ml  of  1%  lignocaine  injection  prior  to  propofol 
administration decreases the incidence.
Clinical uses
Induction of anaesthesia
     The induction dose in healthy adults is 1.5 to 2.5 mg/kg IV, with blood levels of 2 to 6µg /ml 
producing unconsciousness depending on associated medications and the patient’s age.  Awakening 
typically occurs at plasma propofol concentrations of 1.0 to 1.5µg /ml.
keo is the rate constant for equilibration between plasma and the site of drug effect. 
(or) for transfer of drug from the site of drug effect to the environment. 
t½ keo for propofol is 2.4 minutes. 
By knowing the keo of propofol, we can design a dosing regimen that yields the 
desired concentration at the site of drug effect. 
Maintenance of anaesthesia
The typical  dose  of  propofol  for  maintenance  of  anaesthesia  is  100 to  300µg 
/kg/Minute IV, often in combination with a short acting opioid. General anaesthesia with 
propofol  is  generally  associated  with  minimal  post  operative  nausea  and  vomiting 
(PONV) and awakening is prompt with minimal residual sedative effects.
Antiemetic
Sub  hypnotic  doses  of  propofol  are  effective  against  chemotherapy  induced 
nausea and vomiting when administered to induce and maintain anaesthesia, it is more 
effective than ondansetron in preventing PONV.  Mechanism is unknown.
Antipruritic
Propofol,  10  mg  IV,  is  effective  in  the  treatment  of  pruritus  associated  with 
neuraxial opioids or cholestasis.  The quality of analgesia is not affected by propofol.
PHARMACOLOGY OF SEVOFLURANE
   
Sevoflurane is fluorinated methyl isopropyl ether used for inhalational anaesthesia.
Physical Properties
Molecular Weight         - 200 g/mol
Boiling point at 1 atm   - 58.5◦ C
Vapor pressure at 20◦ C - 170 mmHg
Partition coefficient at 37◦ C
Blood - Gas        - 0.69
Brain - Blood    - 1.7
Fat - Blood        -  48
  Oil - Gas            - 47.2
MAC at PB 760 mm Hg.
   30-55 Years of age - 1.8%
   For children
            0-1 month               - 3.3%
            1-6 months             - 3.0%
            6 months - 3 years - 2.8%
            3-12 years              - 2.5%
MECHANISM OF ACTION OF INHALED ANAESTHETICS
     Inhaled  anaesthetics  act  in  different  ways  at  the  level  of  the  central  nervous 
system.  They may disrupt normal synaptic transmission by interfering with the release 
of neurotransmitters from presynaptic nerve terminal (enhance or depress inhibitory or 
excitatory  transmission),  by  altering  the  re-uptake  of  neurotransmitters  to  the  post 
synaptic  receptor  sites,  or  by  influencing the ionic  conductance  change that  follows 
activation  of  the  post  -  synaptic  receptor  by  neurotransmitters.   Both,  pre  and  post 
synaptic effects have been found.
     Direct interaction with the neuronal plasma membrane is very likely, but indirect 
action via production of a second messenger also remains possible.  The high correlation 
between lipid solubility and anaesthetic potency suggests that  inhalation anaesthetics 
have a hydrophobic site of action.  Inhalation agents may bind to both membrane lipids 
and proteins.  It is at this time not clear which of the different theories are most likely to  
be the main mechanism of action of inhalation anaesthetics.
     The Meyer - Overton theory describes the correlation between lipid solubility of 
inhaled anaesthetics and MAC and suggests that anaesthesia occurs when a significant 
number of inhalation anaesthetic molecules dissolve in the lipid cell membrane.  The 
Meyer - Overton rule postulates that the number of molecules dissolved in the lipid cell 
membrane and not the type of inhalation agent causes anaesthesia.  Combinations of 
different  inhaled  anaesthetics  may  have  additive  effects  at  the  level  of  the  cell 
membrane.
     However, the Meyer - Overton theory does not describe why anaesthesia occurs. 
Mullins expanded the Meyer - Overton rule by adding the so-called Critical Volume 
Hypothesis.  He states that the absorption of anaesthetic molecules could expand the 
volume of  a  hydrophobic region within  the  cell  membrane and subsequently  distort 
channels  necessary  for  sodium  ion  flux  and  the  development  of  action  potentials 
necessary for synaptic transmission.  The fact that anaesthesia occurs with significant 
increase in volume of hydrophobic solvents and is reversible by compressing the volume 
of  the  expanded hydrophobic  region of  the  cell  membrane  supports  Mullins  critical 
volume Hypothesis.
The protein receptor hypothesis [postulates that protein receptors in the central 
nervous system are responsible for  the mechanism of action of  inhaled anaesthetics. 
This  theory  is  supported  by the  steep  dose  response  curve  for  inhaled  anaesthetics. 
However,  it  remains  unclear  if  inhaled  agents  disrupt  ion  flow  through  membrane 
channels by an indirect action on the lipid membrane via a second messenger or by 
direct and specific binding to channel proteins.
Another theory describes the activation of Gama Amino Butyric Acid (GABA) 
receptors by the inhalation anaesthetics.  Volatile agents may activate GABA channels 
and  hyperpolarize  cell  membranes.   In  addition,  they  may  inhibit  certain  calcium 
channels  and  therefore  prevent  release  of  neurotransmitters  and  inhibit  glutamate 
channels.   Volatile  anaesthetics  share  therefore  common  cellular  actions  with  other 
sedative, hypnotic or analgesic drugs.  
     The true mechanism of action of volatile anaesthetics may be a combination of 
two or more such theories described as multisite action hypothesis.
Pharmacokinetics
Uptake and distribution of inhaled anaesthetics:-
A series of partial pressure gradients, beginning at the vaporizer of the anaesthetic 
machine,  continuing in the anaesthetic breathing circuit,  the alveolar  tree,  blood and 
tissue will ensure the forward movement of the gas.  The principal objectives of that 
movement are to achieve equal partial pressures on both sides of each single barrier. 
The alveolar partial pressure governs the partial pressure of the anaesthetic in all body 
tissues: they all will ultimately equal the alveolar partial pressure of the gas.  After a 
short  period  of  equilibration  the  alveolar  partial  pressure  equals  the  brain  partial 
pressure.  Alveolar partial pressure can be raised by increasing minute ventilation, flow 
rates at the level of the vaporizer and by using a non- rebreathing circuit.
Two  special  effects  increasing  the  amount  of  gas  in  the  alveoli  have  to  be 
mentioned.  The concentration effect describes how the concentration of the gas in the 
remaining alveolar volume can increase after some of the gas has been transferred into 
the blood.   The second gas effect  usually  refers  to  nitrous  oxide  combined with an 
inhalation agent.  Because nitrous oxide is not soluble in blood, its rapid absorption from 
alveoli  causes  an  abrupt  rise  in  the  alveolar  concentration  of  the  other  inhalation 
anaesthetic.  All the above mentioned factors influence the inflow of gas into the alveoli.
Solubility,  cardiac  output,  and  the  alveolar  to  venous  anaesthetic  gradient 
represent outflow factors.  Inflow factors minus outflow factors equal alveolar partial 
pressure of the gas.
Solubility  describes the affinity of  the gas for  a medium such as blood or  fat 
tissue.  
The  blood:gas  partition  coefficient  describes  how  the  gas  will  partition  itself 
between the two phases after equilibrium has been reached.  The blood: gas coefficient 
of  sevoflurane  (0.69)  ensures  prompt  induction  of  anaesthesia  and  recovery  after 
discontinuation  of  the  anaesthetic.   Compared  with  isoflurane,  recovery  from 
sevoflurane  anaesthesia  is  faster  and  the  difference  is  magnified  in  longer  duration 
surgical procedures (>3 hours).
A higher cardiac output removes more volatile anaesthetic from the alveoli and 
lowers therefore the alveolar  partial  pressure of the gas.   The agent might be faster 
distributed within the body but the partial pressure in the arterial blood is lower.  It will 
take  longer  for  the  gas  to  reach  equilibrium  between  the  alveoli  and  the  brain. 
Therefore, a high cardiac output prolongs induction time.
The alveolar  to venous partial  pressure difference reflects tissue uptake of the 
inhaled anaesthetics.  A large difference is caused by increased uptake of the gas during 
the induction phase. This facilitates the diffusion of the gas from the alveoli into the 
blood.  The brain: blood coefficient describes how the gas will partition itself between 
the  two phases  after  equilibrium has  been reached.   Sevoflurane  for  example  has  a 
brain:blood coefficient of 1.7 meaning that if the gas is in equilibrium, the concentration 
in the brain will be 1.7 times higher than the concentration in the blood.  All inhalation 
anaesthetics have high fat: blood partition coefficients.  This enormous capacity of fat 
for anaesthetic means that most of the anaesthetic contained in the blood perfusing fat is 
transferred to the fat.  Although most of the anaesthetic moves from the blood into the 
fat, the anaesthetic partial pressure in fat increases very slowly.  The large capacity of fat 
and its low perfusion per milliliter explains the delayed recovery in obese patients.
PHARMACODYNAMICS
Central nervous system
     Inhaled anaesthetics cause loss of response to verbal commands at MAC-awake 
concentrations.  Surgical stimulation increases the anaesthetic requirement to prevent 
awareness.
Volatile  anaesthetics  produce  dose  dependent  increases  in  cerebral  blood flow 
(CBF)  .Sevoflurane  has  an  intrinsic  dose  dependent  cerebral  vasodilatory  effect. 
Sevoflurane does not alter auto regulation of CBF.
Inhaled  anaesthetics  produce  increases  in  intracranial  pressure  that  parallel 
increases in CBF produced by them.
Inhaled  anaesthetics  produce  dose  dependent  decreases  in  cerebral  metabolic 
oxygen requirements (CMR O2 ).  When EEG becomes isoelectric, an additional increase 
in the concentration of the volatile anaesthetics does not produce further decreases in 
CMR O2.
Cardiovascular system
Volatile anaesthetics produce dose dependent decreases in mean arterial pressure. 
The decrease produced by sevoflurane principally results from a decrease in systemic 
vascular resistance.
Sevoflurane increases heart rate only at concentrations of >1.5 MAC.  A small dose of opioid 
(morphine in the preoperative medication or fentanyl intravenously immediately before induction of 
anaesthesia) can prevent the heart rate increase associated with volatile anaesthetics.
Volatile anaesthetics exert little or no predictable effect on pulmonary vascular 
resistance.
Sevoflurane has no effect on the atrioventricular or accessory pathways and is 
considered an acceptable anaesthetic drug for patients undergoing ablative procedures.
Volatile  anaesthetics  induce  coronary  vasodilatation  by  preferential  action  on 
vessels with diameters from 20µ to 50 µ. They are cardio protective.
Respiratory system
     Volatile  anaesthetics  produce  dose  dependent  increases  in  the  frequency  of 
breathing and decreases in tidal volume.  The net effect is a rapid and shallow pattern of 
breathing.  The increase in frequency of breathing is insufficient to offset decreases in 
tidal volume, leading to decreases in minute ventilation and increases in PaCO2.
Sevoflurane decreases the ventilatory response to carbon di oxide.  It produces 
apnea  between  1-5  and  2-0  MAC.  All  inhaled  anaesthetics  profoundly  depress  the 
ventilatory response to hypoxemia.
Sevoflurane produces bronchodilatation in normal individuals and in patients with 
COPD.
Skeletal Muscles
Sevoflurane and other fluorinated ethers produce skeletal muscle relaxation and 
produce dose- dependent enhancement of the effects of neuromuscular blocking drugs.
Obstetrics
Volatile anaesthetics produce dose dependent decreases in uterine smooth muscle 
contractility.  This is desirable to facilitate removal of retained placenta.  Conversely, 
uterine relaxation produced by volatile anaesthetics may contribute to blood loss due to 
uterine atony.
Metabolism
3 to 5 % of the dose administered undergoes oxidative metabolism by cytochrome 
P-450  enzymes  to  form  organic  and  inorganic  fluoride  metabolites.   In  addition, 
sevoflurane is degraded by desiccated carbon dioxide absorbents containing strong bases 
to potentially toxic compounds especially when the temperature is increased.  Among 
these compounds, only compound A- Trifluromethyl vinyl ether (and to a lesser extent 
compound B) are encountered clinically.  Compound A is a dose  dependent nephrotoxin 
in  animals.   Although  this  finding  is  a  concern,  the  levels  of  these  compounds 
(particularly compound A) that occur during administration of sevoflurane to patients 
are far below speculated toxic levels.
The  reationale  for  utilizing  at  least  2L/minute  of  fresh  gas  flow  rate  when 
administering sevoflurane is intended to minimize the concentration of compound A that 
may  accumulate  in  the  anaesthesia  breathing  circuit  to  assess  the  adequacy  of  this 
recommendation,  the  concentration  of  compound  A of  anaesthesia  with  1.25  MAC 
sevoflurane during 2 to 8 hours was found to be in the range of 40 to 42 ppm which is 
far below the toxic levels.
     In children, Sevoflurane anaesthesia lasting for  4 hours using total fresh gas flows 
of 2 L/ minute produced concentrations of compound A of <15 ppm, and there was no 
evidence of renal dysfunction.
     A proposed mechanism of nephrotoxicity is metabolism of compound A via beta-
lyase pathway to a reactive thiol.  Because humans have less than one - tenth of the 
enzymatic activity for this pathway compared to rats, it is possible that humans should 
be less vulnerable to injury by this mechanism.
     Probenacid is  a  selective inhibitor  of  organic  anion transport  and pretreatment 
with this  drug prevents  compound,  A-  induced renal  injury     in animals and may 
provide similar protection in humans.
Sevoflurane is non pungent, has minimal odour and causes the least degree of airway irritation 
among the currently available volatile anaesthetics. For these reasons, sevoflurane is acceptable for 
inhalation induction of anaesthesia.
ASSESSMENT OF RECOVERY AND HOME READINESS
For  any  day  care  procedure,  the  assessment  of  recovery  is  of  paramount 
significance.  A discrete  time  interval  is  no  longer  considered  crucial  for  discharge; 
however, the patient must achieve clinical criteria that clearly reflect passage through the 
phases  of  early  and  intermediate  recovery.   The  new  short  acting  anaesthetics  and 
analgesics have been instrumental in the faster recovery now seen after surgery.  Some 
patients are now being transferred directly from the operating table to the step-down unit 
(phase II recovery) bypassing the PACU.  This process is known as ‘fast-tracking’.
STAGES OF RECOVERY
     There are three stages of recovery following ambulatory surgery, namely Early, 
Intermediate  and  Late.   Early  and  intermediate  recoveries  occur  in  the  ambulatory 
surgical facility, whereas late recovery refers to the resumption of normal daily activities 
and occurs after discharge.
Early recovery is the time interval during which patients emerge from anaesthesia, 
recover  their  protective  reflexes  and  resume  motor  activity.   During  this  phase  of 
recovery, patients are cared for in a phase I post anaesthesia care unit (PACU), where 
their vital signs and oxygen saturation are carefully monitored and supplemental oxygen, 
analgesia or antiemetics may be administered.  The Aldrete score is commonly used to 
assess the fitness of patients to be transferred to the phase II recovery area.
Post Anaesthesia Recovery Score (Aldrete Score)
ACTIVITY
2 =  Moves all 4 extremities voluntarily or on command
      1  = Moves two extremities
      0  = Unable to move extremities.
RESPIRATION
      2  = Breathes deeply and coughs effectively
      1  =  Dyspnoeic
       0 = apnoeic
CIRCULATION
2 = BP+  20 % of pre anaesthetic level
      1  = BP+  21- 49% of pre anaesthetic level
      0  = BP+  50 % of pre anaesthetic level.
CONSCIOUSNESS
      2  = Fully awake
      1  = Arousable on calling
       0 = Not responding
OXYGEN SATURATION
       2    = Maintains O2 saturation> 92 % in room air. 
       1    = Needs O2 to maintain saturation >90%
       0     =    O2 saturation < 90 % with O2  supplement.
Total score = 10
>9 is needed for PACU Bypass.
The late recovery period starts when the patient is discharged home and continues 
until full, functional recovery is achieved and the patient is able to return to work.  The 
surgical procedure itself has the highest impact on the full functional recovery.
Fast Tracking
The availability of rapid and short acting anaesthetic drugs for the maintenance of 
general  anaesthesia  has facilitated the early recovery of  outpatients  after  ambulatory 
surgical  procedures.   Patients  may  be  completely  awake  and  oriented,  breathing 
comfortably, with stable vital signs at the time they leave the operating room after brief 
ambulatory surgical procedures done under general anaesthesia.  Significant cost savings 
may be achieved by bypassing the PACU. Care providers  are the major  cost  of  the 
PACU.
Assessment of Home Readiness
     Guidelines for safe discharge from ambulatory surgical facility include stable vital 
signs, return to baseline orientation, ambulation without dizziness, no or minimal pain 
and PONV, and minimal bleeding at the surgical site.  All ambulatory surgical patients 
must have an escort to transport them home, and they must receive written postoperative 
instructions including advice on whom to contract in case a problem develops.
CAUSES OF DELAY IN DISCHARGE
     Delays in  discharge are typically  related to  persistent  symptoms such as pain, 
PONV, dizziness, unsteady gait or, frequently, the lack of an escort.  Excessive pain post 
operatively  is  a  common  surgery  related  cause  of  delayed  discharge.   Planning  an 
appropriate prophylactic analgesic helps to eliminate the delay due to inadequate post 
operative pain relief.
PADSS (Post Anaesthesia Discharge Scoring system)
     A  discharge  scoring  system  has  been  developed  to  evaluate  and  document 
patient’s readiness for discharge objectively.  The PADSS is a simple cumulative index 
that measures patient’s home readiness and is based on five major criteria namely vital 
signs, activity, nausea & vomiting, pain and surgical site bleeding.
     A maximum score of 10 is possible.  Patients achieving a score of 9 or greater and 
have a responsible adult escort are considered fit  for discharge.  The requirement of 
patients to drink and void prior to discharge may not be necessary.
Modified PADSS
VITAL SIGNS (BP & PR) 
2 = Within 20 % of preoperative baseline
1 = 20 % to 40% of preoperative baseline 
0 = > 40 % of preoperative baseline.
AMBULATION
2 = Steady gait, no dizziness
1 = With assistance
0 = No ambulation or with dizziness
NAUSEA & VOMITING
2 = Minimal
1 = Moderate
0 = Severe
PAIN
2 = Minimal
1 = Moderate
0 = Severe
SURGICAL BLEEDING
2 = Minimal
1 = Moderate
0 = Severe
 
REVIEW OF LITERATURE
1. W.Scott  Jellish  et  al.  (1996)6  did  a  study  on  the  comparative  effects  of 
sevoflurane versus propofol in the induction and maintenance of anaesthesia in adult 
patients. They found that induction of anaesthesia time was significantly shorter with 
propofol than with sevoflurane. Emergence times after sevoflurane were significantly 
shorter than propofol.  Overall  frequency of complication-free induction, maintenance 
and emergence did not differ between the two anaesthetic groups. However, side effects 
involving  airway  excitement  were  more  prevalent  during  mask  induction  with 
sevoflurane as compared to propofol.  Sevoflurane compared favorably with propofol 
when used for anaesthesia for elective procedures of 1-3 hours duration.
2. Hanna Viitanen et al. (1999)5 did a study on comparing the induction and 
recovery  characteristics  of  sevoflurane  anaesthesia  induced  with  propofol  or 
sevoflurane.   They  found  that  intubating  conditions  were  similar  in  both  groups. 
Emergence from anaesthesia occurred earlier with sevoflurane for induction than with 
propofol.  The time to meet discharge criteria and recovery at home were similar.
3. Brain Fredman et al. ( 1995)7 did a study on comparison of sevoflurane with 
propofol  for  outpatient  anaesthesia.   They  found  that  induction  of  anaesthesia  with 
propofol was significantly faster than inhalation induction with sevoflurane and there 
was  no  significant  difference  in  the  incidence  of  coughing,  airway  irritation  or 
laryngospasm during induction of anaesthesia.  Though the mean arterial pressures were 
similar, the use of sevoflurane was associated with consistently lower heart rate values 
during the early maintenance period.  The time for fit for discharge was similar among 
the groups.  But the use of sevoflurane for induction and / or maintenance of anaesthesia 
was associated with a higher incidence of postoperative emetic sequelae compared with 
propofol.
4. Hwan  S.  Joo  et  al.  (1999)10 did  a  meta  analysis  on  sevoflurane  versus 
propofol  for  anaesthetic  induction.   They  found  that  sevoflurane  and  propofol  had 
similar  efficacy  for  anaesthetic  induction.   However,  for  routine  outpatient  surgery, 
propofol  may  still  be  the  preferred  induction  anaesthetic  because  of  its  favorable 
induction characteristics, high patient satisfaction and less incidence of PONV.
5. J.K.  Moore  et  al.  (2003)8 did  a  study  on  induction  and  recovery 
characteristics  of  propofol  and  halothane  versus  sevoflurane  in  paediatric  day  case 
surgery.   They  found  that  induction  time  was  shorter  with  sevoflurane.   Excitatory 
movement was more common during induction with sevoflurane.  Incidence of delirium 
in recovery and PONV were higher in the sevoflurane group.
6. Reader.  J  et  al.(1997)13 did  a  study  on  recovery  characteristics  of 
sevoflurane  or  propofol  based  anaesthesia  for  day  care  surgery.   They  found  that 
maintenance of anaesthesia with sevoflurane results in a more rapid emergence, but a 
higher incidence of nausea and vomiting compared with propofol.  However the side 
effects were minor and did not result in any difference in time to discharge from the 
recovery ward or the hospital.
7. Chung, Frances, MD, FRCPC (1995) did a study and concluded that the 
post Anaesthesia Discharge scoring system (PADSS) is simple, practical, and easy to 
apply  and  to  remember.   In  addition  to  permitting  a  uniform  assessment  of  home 
readiness for patients, PADSS establishes a pattern of routine repetitive evaluation of 
patient’s home readiness that is likely to contribute to improved patient outcome.
8. Leticia  Delgado  –  Herrera  et  al.  (2001)4 in  their  review  state  that 
sevoflurane  possess  a  number  of  characteristics  that  approach  those  of  the  ideal 
anaesthetic. Sevoflurane is versatile and can be used both as a mask induction inhalation 
anaesthetic and a maintenance agent for paediatric and adult surgical procedures.
9. V.  Picard et al. (2000)17 did a study on the quality of recovery in children: 
Sevoflurane versus propofol and they found that emergence and recovery times were 
comparable in both groups.  There was a significant greater incidence of postoperative 
agitation in the sevoflurane group compared with the propofol group.  This, did not, 
however  delay  discharge  from  the  recovery  room.   The  incidence  of  nausea  and 
vomiting was not significantly different among the groups.
10. Cynthia A. Lien et al. (1996)14 did a study on comparison of the efficacy of 
Sevoflurane – Nitrous oxide or Propofol – Nitrous oxide for induction and maintenance 
of  general  anaesthesia  in  adults.   They  found  that  induction  of  anaesthesia  was 
significantly slower in the sevoflurane group than in the propofol group.  The ease of 
induction and the time required for emergence from the anaesthesia were same in both 
the  groups.   Patients  in  sevoflurane  group  experienced  nausea  and  vomiting  more 
frequently  than  patients  in  the  propofol  group  which  were  not  related  to  the 
administration of neostigmine or intraoperative opioids.
11. Julia  C.F.  Greenspun  et  al.  (1995)11 did  a  study  on  comparison  of 
sevoflurane and halothane anaesthesia in children undergoing outpatient Ear, Nose and 
Throat  surgery  and  found  that  sevoflurane  anaesthesia  had  faster  recovery  than 
halothane anaesthesia in premedicated patients, but there was no difference in the time 
to meet home discharge criteria.
12. Sahar  M. Siddik – Sayyid et  al.  (2005)12 did a  study on comparison of 
Sevoflurane  –  Propofol  versus  Sevoflurane  or  Propofol  for  Laryngeal  Mask  Airway 
insertion in adults and found that the co induction technique was associated with the 
most  frequent  incidence of  successful  LMA insertion at  the first  attempt  than either 
sevoflurane  or  propofol  alone.   Propofol  induced  anaesthesia  allowed  the  fastest 
insertion of LMA and was associated with the least frequent incidence of PONV.
13. Anil  Gupta  et  al.  (2004)18 did  a  systematic  review  on  comparison  of 
recovery profile after ambulatory anaesthesia with propofol, isoflurane, Sevoflurane and 
desflurane.  They conclude that the differences in the early recovery times among the 
different anaesthetics were small and in favor of the inhaled anaesthetics.  The incidence 
of side effects specifically post operative nausea and vomiting was less frequent with 
propofol.
14. Nicole Assman et al. (2004)15 say that postoperative pain is one of the most 
common causes  of delayed discharge and unplanned admission.   PONV is a major 
cause of patient dissatisfaction with day care surgery.  Opioid analgesics are important 
causative factors in PONV and therefore there is a trend away from using morphine (or 
at least to minimize the dose).  Paracetamol or Non steroidal Anti inflammatory Drugs 
can be used.
15. Yaruz Guekan et al. (1999)16 did a study on Propofol – Nitrous oxide versus 
Sevoflurane  –  Nitrous  Oxide  for  strabismus  surgery  in  children  and  found  that  the 
overall  incidence  of  vomiting  and antiemetic  requirement  in  the  first  24  hours  was 
significantly higher in Sevoflurane – Nitrous oxide group than Propofol – Nitrous oxide 
group and the Propofol – Nitrous oxide group had significantly more episodes of oculo 
cardiac reflex than sevoflurane – nitrous oxide group.
16. K. R. Watson et al. (2000)9 did a study on the clinical comparison of single 
agent anaesthesia with sevoflurane versus target controlled infusion of propofol.  They 
found that propofol had a significantly faster induction time than sevoflurane but was 
associated  with  double  the  incidence  of  involuntary  movements.   Emergence  times, 
characteristics,  post  operative nausea and vomiting and pain  were  unaffected  by the 
anaesthetic  technique.   However,  a  more  predictable  emergence  time  was  found 
following  sevoflurane.   Cardiovascular  stability  was  good  and  comparable  in  both 
groups.
17. A.  Thwaites  et  al.  (1997)19 did  a  study  on  inhalation  induction  with 
sevoflurane: a double - blind comparison with propofol. They found that induction of 
anaesthesia with sevoflurane was significantly slower when compared with propofol, but 
was  associated  with  a  lower  incidence  of  apnoea  and  a  shorter  time  to  establish 
spontaneous ventilation.  Induction complications were uncommon in each group but the 
transition to maintenance was smoother with sevoflurane and was associated with less 
hypotension  compared  with  propofol.   Emergence  occurred  significantly  earlier 
compared with propofol.
18. Anton. A. van den Berg et al. (2005)21 did an audit of preoperative patient 
preferences for intravenous or inhaled induction of anaesthesia in adults and found that 
33%  selected  IV  induction,  50%  chose  inhaled  induction  and  17%  patients  were 
undecided.
19. Mary E. Molloy,  FFARCSI,  Donal J.  Buggy, MD, MSc,  MRCPI,  DME, 
FFARCSI, Patrick Scanlon, FFARCSI(1999) did a study on propofol or sevoflurane for 
laryngeal  mask  airway  insertion  and  found  that  modified  vital  capacity  breath 
inhalational induction with sevoflurane 8% is efficient for LMA insertion in most cases, 
but takes slightly longer than propofol.
20. Masaki Yurino et  al.  (1993)20  did a study on comparison of spontaneous 
ventilation and vital capacity rapid inhalation induction (VCRII) techniques in induction 
of  anaesthesia  with sevoflurane,  nitrous oxide and oxygen.  They found that  VCRII 
required only half the time of conventional inhalation induction and was not associated 
with cardiovascular instability.  Each of the two techniques was found acceptable by 
most of the volunteers studied.
21. Suntheralingam  Yogendran  et  al.  (2005)22 did  a  study  comparing  vital 
capacity and patient controlled sevoflurane inhalation induction and found that PCI was 
comparable to VCI in sevoflurane induction with respect to the speed of induction, side 
effects  during  induction  and  patient  satisfaction.  However,  PCI  requires  no  special 
training and is widely applicable to all patient populations
MATERIALS AND METHODS
This study was carried out  in the ENT theatre,  Government General  Hospital, 
Chennai after obtaining ethical committee and institutional approval.  The aim of the 
study  was  to  compare  the  induction  and  recovery  characteristics  of  propofol  and 
sevoflurane when they are used as single induction and maintenance anaesthetic agent in 
adult day care tonsillectomies.
STUDY DESIGN
     The study was a randomized prospective study.
SELECTION OF CASES
     Forty patients undergoing tonsillectomy were selected for the study.  Their age ranged from 13 
to 40 years.  All the patients were assessed and those with normal clinical, biochemical, radiological 
and haematological parameters were selected.  Informed written consent was obtained from all the 
patients and parents in case of minor.  Each patient was randomly allocated to either the propofol or the 
sevoflurane group by lots.  The groups were named ‘P’ for propofol and ‘S’ for sevoflurane.
INCLUSION CRITERIA
Assessed patients of ASA physical status I & II
          Normal biochemical and haematological parameters
          Age group between 13 to 40 years
          No known hypersensitivity to egg or drugs
          Airway – MPC I & II
          Undergoing tonsillectomy and adenoidectomy
          Surgery lasting around one hour
          Patients normally able to ambulate well
          Educated attender who can understand and carryout                   instructions.
EXCLUSION CRITERIA
Patient not willing
          ASA class III and above
          Patients with H/O drug or egg allergy
          Anticipated difficult airway
          H/O serious adverse experience with anaesthesia          
          Severe CVS/RS/CNS/ Metabolic disease
MATERIALS
1.  Anaesthesia machine with sevoflurane vaporizer.
2.   Appropriate drugs in labeled, preloaded syringes.
3.   functioning Laryngoscope with appropriate size blades
4.  Appropriate sized endotracheal tubes,
5.  Equipments and drugs for resuscitation.
METHODS
Preoperative preparation
Patients were assessed pre-operatively. Procedure was explained to the patient and informed 
consent obtained.  They were assessed with particular attention to any contraindications.  The tests for 
recovery and the importance of strictly following instructions were emphasized.
Premedication
     The patients were not given any IM premedication.  No prophylactic antiemetic 
was given.  All the patients received Glycopyrrolate 5µg/kg and Fentanyl 2 µg/kg just 
before induction of anaesthesia.
Conduct of Anaesthesia
     On arrival  of  the patient  in  the operating room, monitors  like pulse oximetry, 
NIBP and ECG were connected and baseline values of HR, BP and SPO2 were recorded. 
An intravenous access was obtained in the nondominant arm. 2% IV Lignocaine 1cc was 
given before induction to both the groups. Although lignocaine was given as prophylaxis 
against pain on injection of propofol,  it  was administered to both groups of patients 
because of possible effects on haemodynamic variables and to make it a constant.
PROPOFOL GROUP
The patients were induced with propofol 2mg/kg IV and intubated with 1.5mg/kg 
succinylcholine.  After confirming and securing the endotracheal tube in position, they 
were connected to the closed circuit  with nitrous oxide and oxygen in 2L: 1L ratio. 
Immediate  post  intubation,  this  group  of  patients  received  a  continuous  infusion  of 
propofol 6-12mg/kg/hr (100-200 µg/kg/mnt) to maintain an adequate depth of anesthesia 
as judged by clinical signs and haemodynamic responses to surgical stimuli. Ventilation 
was controlled with vecuronium 0.8 mg/kg as the loading dose and one fourth of the 
loading dose as top up dose.  They were given Diclofenac injection IM after intubation.
SEVOFLURANE GROUP
     The  patients  are  induced with  sevoflurane  4% by  patient  controlled  inhalation 
induction i.e. spontaneous ventilation (Penlon sigma Delta vaporizer) in Nitrous Oxide 
and oxygen in 4L:  2L ratio  and intubated  with  1.5mg/kg of  succinylcholine.   After 
confirming and securing the endotracheal tube in position, they were connected to the 
closed circuit with nitrous oxide and oxygen in 2L: 1L ratio with sevoflurane 1-2.5% to 
maintain  adequate  depth of  anaesthesia.  Ventilation  was controlled  with vecuronium 
0.8mg/kg as loading dose and  one fourth of the loading dose as top up dose.  This group 
also received Diclofenac injection 1M after intubation.
Monitoring
Throughout the procedure, HR, ECG and SPO2 were monitored continuously and 
NIBP was monitored every 5 minutes.
Recovery
     Upon completion of the surgery, residual neuromuscular block was reversed with 
neostigmine  50µg/kg  and  glycopyrrolate  10µg/kg  and  then    anaesthesia  was 
discontinued.  The patients’ lungs were ventilated with 100% O2 at a flow rate of 8L/mnt 
until tracheal extubation.  The time of discontinuing the agent was taken as ‘time zero’ 
to calculate the recovery time.
Parameters studied
1. TIME TO LOSS OF CONSCIOUSNESS
           Time interval from the start of induction to loss of eyelash reflex.
2. INDUCTION COMPLICATIONS
1. Desaturation
2. Coughing 
3. Laryngospasm
4. Patient movement
3. INCIDENCE OF APNOEA
4. TIME TO PHASE I RECOVERY
          This is the time taken from discontinuation of propofol or sevoflurane to the  time 
when Aldrete score is ≥ 9.          
5. TIME TO PHASE II RECOVERY
          This is the time taken from discontinuation of propofol or sevoflurane to the time 
when the PADSS score is ≥ 9. It is also taken as the time to home readiness.
Statistical analysis
The  descriptive  statistics  of  the  variables  studied  are  represented  as  two-way 
tables.   The categorical factors are represented by the number and frequency (%) of 
cases.  The continuous variables are represented by measures of central frequency (like 
mean, median) and deviation (say, standard deviation and range.)  The differences in the 
properties are tested for statistical significance using non-parametric Chi-square test for 
variables measured on nominal  scale.  For variables measured on a continuous scale, 
when testing for two groups, Student “t” test is used to test for statistical significance in 
the differences of the two means.
OBSERVATIONS AND RESULTS
The patients included in the study were divided into two groups consisting of twenty patients each.
                 Group P (n=20) received Propofol Anaesthesia
                 Group S (n=20) received Sevoflurane Anesthesia
Table 1
Distribution of age of cases by groups$
Age Group P Group S p-value
No. of cases
Mean
20
20.4
20
17.6
0.25
S.D.
Median
Range
7.59
16.5
13 – 38
7.92
14
12 – 40
$ Not statistically significant
      The  mean age  was observed to  be greater  in  Group P than Group S but  not 
statistically significant.
Table 2
Distribution of cases by groups and sex$
Sex
Group P 
(n=20)
Group S 
(n=20) p-value
No. % No. %
Male
Female
9
11
45.0
55.0
10
10
50.0
50.0
0.75
$ Not statistically significant
A female preponderance was forthcoming in Group P and equally distributed in 
Group S. The difference in the distribution between the two groups is not statistically 
significant. 
Table 3
Distribution of weight of cases by groups$
Weight Group P Group S p-value
No. of cases
Mean
S.D.
Median
Range
20
43.8
11.68
40
30 – 60
20
40.0
8.89
40
30 – 60
0.26
$ Not statistically significant
The distribution of cases by weight and the difference in the mean values were 
observed to be not statistically significant between Group P and Group S. 
 
Table 4
Distribution of cases by ASA and groups$
ASA
Group P 
(n=20)
Group S 
(n=20) p-value
No. % No. %
Grade I
Others
20
0
100.0
0.0
20
0
100.0
0.0
1.00
$ Not statistically significant
     All the cases from both groups were identically classified as Grade I on ASA. Hence, 
there are no differences on ASA between the two groups.
Table 5
Distribution of cases by MPC and groups$
MPC Group P 
(n=20)
Group S 
(n=20) p-value
No. % No. %
Grade I
Grade II
16
4
80.0
20.0
19
1
95.0
5.0
0.34
$ Not statistically significant
     The distribution of number of cases by MPC and the two groups was not statistically 
significant  (p=0.34) with more proportion of  Grade I  cases in  among Group S than 
Group P.
Table 6
Distribution of cases by groups and MAP
MAP
Group P
(n=20)
Group S
(n=20) p-value for difference of 
mean 
differenceActual
Difference 
from 
reference
Actual
Difference 
from 
reference
PRE-OP$
Mean
SD
92.6
9.42
- 93.7
8.38
- -
At 
inducti
on
Mean
SD
80.6
11.59
   -12.0
8.21
87.1
14.96
 -6.6
12.85
0.12
POST-OP
Mean
SD
92.8
 9.47
 0.25
10.56
92.9
13.01
-0.75
13.56
0.80
At 
discha
rge
Mean
SD
88.0
6.30
-4.55
6.68
93.4
7.42
-0.30
7.72
0.07
$ Reference category; Not statistically significant
The actual mean MAP values were generally lesser in Group P than Group S at all 
time points studied. The differences in the mean values of MAP at induction, Post-op 
and at discharge compared to the reference value at Pre-op between the two groups was 
observed to be statistically not significant. 
Table 7
Distribution of cases by groups and pulse rate
Pulse rate
Group P
(n=20)
Group S
(n=20)
p-value 
for 
difference 
of mean 
difference
Actual
Difference 
from 
reference
Actual
Difference 
from 
reference
PRE-OP$
Mean
SD
91.6
11.88
- 97.3
15.39
-
At induction
Mean
SD
105.8
11.52
14.2
10.85
98.8
25.19
1.6
21.34
0.02*
POST-OP
Mean
SD
89.4
12.71
-2.25
10.94
99.5
17.48
 2.25
20.49
0.39
At discharge
Mean
SD
87.4
9.54
-4.2
9.45
95.3
11.15
-2.0
14.44
0.57
$ Reference category; * statistically significant
The actual mean pulse rate values were generally lesser in Group P than Group S at all time points 
except at induction. The differences in the mean values at induction, Post-op and at discharge 
compared to the reference value at Pre-op between the two groups was observed to be statistically 
significant at induction and not at other time points.
Table 8
Distribution of time to LOC by groups
Time to 
location Group P Group S p-value
No. of cases
Mean
S.D.
Median
Range
20
39.8
17.13
35
20 – 90
20
71.6
26.28
75
20 – 140
<0.001*
* Statistically significant
The mean time to LOC was observed to be lesser in Group P than Group S and the 
difference was statistically significant (p<0.001).
Table 9
Distribution of cases by incidence of apnoea and groups$
Apnoea Group P 
(n=20)
GroupS 
(n=20) p-value
No. % No. %
No
Yes
2
18
0.0
90.0
2
18
10.0
90.0
1.00
$ Not statistically significant
There were equal number of cases with incidence of apnoea among both groups 
and the difference in distribution was statistically not significant.
Table 10
Distribution of cases by induction complication and group
Induction 
complication
Group P
(n=20)
Group S
(n=20) p-value
No. % No. %
Nil
Yes
19
1
95.0
5.0
13
7
65.0
35.0
0.04*
Complication type
Patient movement
Bronchospasm
Bradycardia
0
1
0
0.0
5.0
0.0
3
3
1
15.0
15.0
5.0
* Statistically significant
The number of cases with induction complications was more among Group S than 
Group P and difference was statistically significant (p=0.04). 
Table 11
Distribution of Phase I recovery by groups$
Phase I 
recovery profile GroupP Group S p-value
No. of cases
Mean
S.D.
Median
Range
20
12
2.62
11
8 – 17
20
11
2.34
10
8 – 17
0.21
$ Not statistically significant
The distribution of Phase I recovery profile between Group P and Group S is not 
statistically significant (p=0.21).
Table 12
Distribution of phase II recovery by groups
Phase II 
recovery profile Group P Group S p-value
No. of cases
Mean
S.D.
Median
Range
20
105.5
11.11
105
85 – 110
20
97.5
12.06
97.5
80 – 130
0.10
$Not Statistically significant
The distribution of Phase II  recovery profile  between Group P and Group S is   not 
statistically significant (p=0.01).
Table 13
Distribution of cases by post operative nausea/vomiting and group
Post operative 
nausea/vomiting
Group P
(n=20)
Group S 
(n=20) p-value
No. % No. %
Nil
Yes
14
6
70.0
30.0
9
11
45.0
55.0
0.20
$ Not Statistically significant
The distribution of post operative nausea / vomiting is less in Group P, but not 
statistically  significant.  
Table 14
Distribution of cases by post operative pain and group
Post operative 
pain
Group P
(n=20)
Group S
(n=20) p-value
No. % No. %
Nil
Yes
16
4
80.0
20.0
14
6
70.0
30.0
0.72
$ Not Statistically significant
The distribution of post  operative pain is less in Group P,  but  not statistically 
significant. 
DISCUSSION
Intravenous agents are used commonly for induction of anaesthesia followed by 
inhalational  agents for  maintenance.   A problem with this technique is the transition 
phase from induction to maintenance.  The rapid redistribution of the intravenous agent 
could lead to lightening of anaesthesia before an adequate depth is attained with the 
inhalational  agent.   This  has promoted the rediscovery of  ‘single  agent’ anaesthesia, 
which avoids problems associated with a transition phase.9
Propofol  is  a  short  acting  general  anaesthetic  agent  used  widely  for  total 
intravenous anaesthesia because of its favorable recovery profile and low incidence of 
side effects.  Propofol infusions are also becoming increasingly popular for maintenance 
of  anaesthesia.   However,  use  of  propofol  is  associated  with  pain  on  injection, 
cardiovascular  and  respiratory  depression  and  requires  an  intravenous  drug  delivery 
system  6, 7, 9 
Sevoflurane  is  a  safe  and  versatile  inhalational  anaesthetic  compared  with 
currently  available  agents.   Sevoflurane  is  useful  in  adults  and  children  for  both 
induction and maintenance of anaesthesia in inpatient and outpatient surgery.  Of all 
currently  used  anaesthetics,  the  physical,  pharmacodynamic,  and  pharmacokinetic 
properties  of  sevoflurane  come  closest  to  that  of  the  ideal  anaesthetic.   These 
characteristics include inherent stability, low flammability, non – pungent odour, lack of 
irritation to airway, low blood: gas solubility allowing rapid induction of and emergence 
from anaesthesia, minimal end-organ effects, minimal effect on cerebral blood flow, low 
reactivity with other drugs and a vapour pressure and boiling point that enables delivery 
using standard vapourisation techniques.  8  The availability of this agent makes it an 
alternative option for volatile Induction and Maintenance Anaesthesia (VIMA). 9
Anton A. van den Berg, FRCA, Dudley A. Chitty, MD, Ramoun D. Jones, MD, Mir S. Sohel, MD 
and Ali Shahen, MD in their audit on preoperative patient preferences for induction of anaesthesia in 
adults found that 33% selected IV induction, 50% chose inhaled induction and 17% patients were 
undecided.  They conclude that where manpower and facilities permit and in the absence of risk of 
regurgitation or airway difficulty, it is suggested that enquiry may be made of healthy adults 
presenting for elective ambulatory surgery as to their preferred route for  the induction of 
anaesthesia. The inhalation induction done in our study was based on the above study.
A. Thwaites, S. Edmends and I. Smith in their study of inhalation induction with sevoflurane versus 
intravenous induction with propofol conclude that induction of anaesthesia with sevoflurane was 
significantly slower compared with propofol, but was associated with a lower incidence of apnoea 
and a shorter time to establish spontaneous ventilation.
Brain Fredman, MH. Nathanson, I. Smith, J. Wang, K. Klein and PF. White in 
their  study  of  sevoflurane  versus  propofol  was  significantly  faster  than  inhalation 
induction with sevoflurane and there were no significant difference in the incidence of 
coughing, airway irritation or laryngospasm during induction of anaesthesia.
In our study, we found that induction with sevoflurane is longer and associated 
with more complications.  This is in concurrence with the study done by W. Scott Jellish, 
MD, PhD, Cynthia A. Lien, MD, H. Jerrel Fontenot, MD, PhD, and Richard Hall, MD, 
FRCPC,  FCCPS  comparing  the  induction  and  maintenance  of  anaesthesia  in  adult 
patients with sevoflurane and propofol.   They found that induction of anaesthesia is 
shorter with propofol. And side effects involving airway excitement were more during 
mask  induction  with  sevoflurane  as  compared  to  propofol.   This  explains  the  more 
incidence of bronchospasm observed in the sevoflurane group.
The patient movement during intubation were slight movements of the hands or 
feet and did not compromise tracheal intubation or haemodynamics. 5   The observation 
of increase in the incidence of patient movement during induction with sevoflurane is 
supported by the study done by J.K. Moore, E.W.Moore, R.A. Elliott, A.S. St. Leger, K. 
Payne and J. Kerr on comparing the induction and recovery characteristics of propofol 
and sevoflurane.
Both propofol and sevoflurane produce dose dependent depression of ventilation 
and produce apnoea. Opioids given as premedication enhance this ventilatory depressant 
effort2. This explains the increased incidence of apnoea observed in both groups.
Though MAP decreased during induction of anaesthesia in both groups, the fall in 
MAP is  more  with  induction  of  anaesthesia  with  propofol.5    HR  increased  during 
induction of anaesthesia in both groups.  This was probably due to the administration of 
glycopyrrolate prior to induction. 5,6
The occurrence of bradycardia in one patient during induction of anaesthesia with 
sevoflurane could be explained by the direct sevoflurane induced inhibition of the beta-
adrenoceptor system.13
Though statistically not significant, phase I recovery i.e. emergence from anaesthesia is shorter with 
sevoflurane than with propofol.  This is in concurrence with the study done by A. Thwaites, S. 
Edmends and I. Smith on comparing the induction of anaesthesia with sevoflurane and propofol.
In our study, we found that the phase II recovery time after induction and maintenance of 
anaesthesia with propofol and sevoflurane were comparable.  But the incidence of postoperative 
nausea and vomiting is more with sevoflurane anaesthesia and the number of patients complaining 
pain were more with sevoflurane anaesthesia.  This observation is supported by the studies done by 
Brain Fredman et al (1995), Cynthia A Lien et al (1996), Reader. J et al (1997), Hanna Viitanen et al 
(1999) and V. Picard et al (2000).
The lower incidence of postoperative nausea and vomiting in the propofol group 
may be related to the ‘intrinsic’ antiemetic property of propofol. 7  The shorter time for 
requiring postoperative analgesics in the sevoflurane group probably reflects its rapid 
recovery profile and lack of tissue solubility and accumulation.  It has been speculated 
that but not substantiated that propofol may have some analgesic effects.  6     
SUMMARY
Despite the low blood: gas solubility of sevoflurane, the inhalation induction of 
anaesthesia was slower than intravenous induction with propofol.  Though the incidence 
of induction complications was more with sevoflurane group, they did not compromise 
tracheal  intubation  or  haemadynamics  except  severe  bradycardia  observed  in  one 
patient.
The  increased  incidence  of  apnoea  in  both  groups  is  attributable  to  the 
enhancement of the ventilatory depressant  effect  of  propofol  and sevoflurane by the 
opioid  fentanyl .
The  shorter  emergence  time  in  the  sevoflurane  group  did  not  translate  into  a 
shorter hospital study.  And the increased incidence of PONV and pain did not affect the 
time for home readiness.
Though  the  small  sample  size  in  our  study  precludes  drawing  statistical 
conclusions, sevoflurane is found to be a useful alternative for elective procedures of 
short duration.
CONCLUSION
On comparing the induction and recovery characteristics of propofol and sevoflurane 
in adult tonsillectomies, it was found that:-
• Induction with sevoflurane is slower and with more complications.
• Incidence of apnoea is equal in both groups.
• Phase I & II recovery times were comparable between both groups.
• Sevoflurane anaesthesia was associated with high PONV and  postoperative 
pain rate which is statiscally not significant. 
• The smoother induction and less post operative PONV and pain with propofol 
make  it  more  ideal  for  induction  and  maintenance  of  anaesthesia  in  adult 
outpatient surgeries.
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PROFORMA
DEPARTMENT OF ANAESTHESIOLOGY,
MADRAS MEDICAL COLLEGE, CHENNAI
COMPARISON  OF  INDUCTION  AND  RECOVERY  CHARACTERISTICS  OF 
PROPOFOL AND SEVOFLURANE IN DAY CARE ADULT TONSILLECTOMIES 
1. Name                       :
2. Age/Sex :
3. IP NO/Unit :
4. PREOP
                    1. Comorbidity                                7. PR
                    2. Weight                                         8. BP
                    3. Hb %                                           9. SPO2
                    4. Blood Sugar                              10. CVS
                    5. Blood Urea                                11. RS
                    6. Serum Creatinine                      12. ASA PS / MPC
Group S Group P
Drug   Dose given Drug   Dose given 
Glyco 5µg/kg Glyco 5µg/kg
Fent 2µg/kg Fent 2µg/kg
Sevoflurane
4%  with  67% 
N2O in 6L/mnt 
Propofol .2mg/kg
Succinyl  choline 
1.5 mg/kg 
Succinyl  choline 
1.5 mg/kg 
VARIABLES ASSESSED:
1. Time to LOC in sec
2.  Incidence of apnoea
3. Induction complications
Duration of procedure
Duration of Anaesthesia
Time since discontinuing sevoflurane / Propofol to recovery
Phase I  (Aldrete /score ≥ 9)
Phase II (PADSS Score ≥ 9)
Time MAP PR SPO 2
Preop  
Induction
Maintenance
1. 5 minutes 
2. 10 minutes 
3. 15 minutes
4. 20 minutes
5. 25 minutes
6. 30 minutes
7. 35 minutes
8. 40 minutes
9. 45 minutes
10. 50 minutes
11. 55 minutes
12. 60 minutes
MASTER CHART
SI.NO AGE SEX WEIGHT ASA MPC GROUP SI.NO AGE SEX WEIGHT ASA MPC GROUP
1 26 F 50 I I P 21 14 F 40 I I S
2 31 M 60 I I P 22 26 F 50 I I S
3 25 F 40 I I P 23 15 M 50 I I S
4 27 M 60 I I P 24 13 M 30 I I S
5 15 F 35 I I P 25 16 M 35 I I S
6 22 F 45 I I P 26 13 M 30 I I S
7 15 M 30 I I P 27 13 M 30 I I S
8 14 M 30 I I P 28 13 F 40 I I S
9 15 M 30 I I P 29 14 M 30 I I S
10 13 F 30 I I P 30 13 F 30 I I S
11 15 F 30 I I P 31 35 F 50 I I S
12 18 F 40 I I P 32 13 M 35 I I S
13 15 F 50 I II P 33 16 F 40 I II S
14 13 M 40 I I P 34 18 F 40 I I S
15 30 M 60 I II P 35 40 F 60 I I S
16 14 F 35 I I P 36 13 M 40 I I S
17 38 F 60 I I P 37 13 M 50 I I S
18 18 M 50 I I P 38 26 F 50 I I S
19 30 F 60 I II P 39 13 F 35 I I S
20 14 M 40 I II P 40 15 M 35 I I S
INDUCTION PROFILE
SI.NO
TIME TO
LOC IN 
SEC
INCIDENCE
OF  APNOEA
INDUCTION
COMPLICATION
SI.NO
TIME TO
LOC IN 
SEC
INCIDENCE
OF  APNOEA
INDUCTION
COMPLICATION
1 90 Yes NIL 21 75 Yes Pt.movement
2 60 Yes NIL 22 75 Yes Pt.movement
3 40 Yes NIL 23 75 Yes Bronchospasm
4 40 Yes NIL 24 52 Yes NIL
5 75 Yes NIL 25 90 Yes NIL
6 30 Yes Bronchospasm 26 60 Yes Bronchospasm
7 70 Yes NIL 27 60 No NIL
8 45 Yes NIL 28 60 Yes NIL
9 40 Yes NIL 29 75 Yes NIL
10 20 Yes NIL 30 50 Yes NIL
11 30 Yes NIL 31 75 Yes Bronchospasm
12 30 Yes NIL 32 120 Yes NIL
13 35 Yes NIL 33 90 Yes NIL
14 30 Yes NIL 34 60 Yes NIL
15 25 Yes NIL 35 20 Yes Bradycardia
16 30 Yes NIL 36 50 Yes NIL
17 45 Yes NIL 37 40 Yes Bronchospasm
18 35 Yes NIL 38 140 Yes Pt.movement
19 30 Yes NIL 39 90 No NIL
20 35 No NIL 40 75 No NIL
MEAN ARTERIAL PRESSURE
SI.NO PREOP INDUCTION POSTOP DISCHARGE SI.NO PREOP INDUCTION POSTOP DISCHARGE
1 74 61 94 82 21 98 97 85 100
2 86 79 91 81 22 97 124 76 83
3 99 90 109 96 23 82 82 77 89
4 84 79 89 86 24 99 95 111 88
5 88 78 90 84 25 99 67 90 109
6 95 72 75 97 26 102 78 99 95
7 103 83 98 94 27 107 95 101 99
8 97 80 92 85 28 91 71 70 90
9 87 79 102 92 29 105 104 99 100
10 86 83 88 86 30 75 57 84 81
11 80 61 78 79 31 81 80 116 93
12 92 93 98 88 32 99 94 93 99
13 110 95 87 91 33 96 98 99 99
14 101 87 87 86 34 86 97 89 97
15 100 77 106 90 35 90 78 83 86
16 80 56 81 73 36 90 75 105 99
17 105 101 111 97 37 99 85 115 100
18 95 93 92 89 38 94 90 79 86
19 90 88 94 91 39 97 96 99 90
20 99 74 94 93 40 86 79 88 84
PULSE CHART
SI.NO PREOP INDUCTION POSTOP DISCHARGE SI.NO PREOP INDUCTION POSTOP DISCHARGE
1 86 108 92 82 21 97 113 76 102
2 94 90 77 80 22 81 86 84 84
3 105 116 116 98 23 99 102 84 88
4 89 100 93 80 24 117 129 88 102
5 92 98 86 84 25 102 93 78 96
6 103 120 92 89 26 110 111 111 83
7 77 96 78 74 27 87 92 110 84
8 97 118 76 80 28 102 76 77 86
9 87 104 96 94 29 73 118 90 96
10 113 123 112 108 30 95 82 114 93
11 91 113 97 94 31 70 88 123 103
12 74 124 98 82 32 124 118 108 108
13 96 105 90 90 33 118 142 121 114
14 91 102 78 90 34 108 124 117 98
15 77 88 70 78 35 86 24 92 78
16 98 102 92 104 36 84 76 110 106
17 113 116 107 86 37 104 102 105 96
18 92 102 78 83 38 82 88 75 78
19 68 84 76 74 39 115 110 130 116
20 89 107 83 98 40 91 102 97 94
RECOVERY PROFILE
SI.NO
DURATION OF
ANAESTHESIA
(IN MNTS)
PHASE i
RECOVERY
(IN MNTS)
PHASE II
RECOVERY
(IN MNTS)
SI.NO
DURATION OF
ANAESTHESIA
(IN MNTS)
PHASE i
RECOVERY
(IN MNTS)
PHASE II
RECOVERY
(IN MNTS)
1 48 10 110 21 60 9 90
2 26 16 120 22 55 10 95
3 28 14 125 23 40 11 105
4 40 11 110 24 52 10 100
5 50 11 100 25 55 12 110
6 76 12 110 26 32 9 85
7 65 15 130 27 28 10 95
8 47 9 100 28 50 10 100
9 60 11 110 29 45 12 95
10 75 17 105 30 55 14 125
11 40 8 95 31 48 17 100
12 66 14 110 32 74 13 130
13 57 10 100 33 44 8 80
14 47 9 95 34 35 9 100
15 50 15 110 35 24 10 95
16 60 12 100 36 41 12 105
17 74 11 85 37 30 8 85
18 55 15 90 38 76 11 95
19 38 10 105 39 42 10 100
20 37 10 100 40 36 15 95
PONV AND PAIN
SI.NO PONV PAIN SI.NO PONV PAIN
1 NO NO 21 YES YES
2 NO NO 22 NO NO
3 YES NO 23 YES NO
4 NO YES 24 YES YES
5 NO NO 25 NO NO
6 YES YES 26 YES NO
7 NO NO 27 YES YES
8 NO NO 28 YES NO
9 YES NO 29 NO NO
10 NO NO 30 NO YES
11 NO NO 31 NO NO
12 YES NO 32 NO NO
13 YES YES 33 YES NO
14 NO NO 34 NO NO
15 NO NO 35 YES NO
16 YES NO 36 NO NO
17 NO YES 37 YES NO
18 NO NO 38 YES NO
19 NO NO 39 YES YES
20 NO NO 40 NO YES

